Top Cholera Vaccines Companies

Global Cholera Vaccines Market size was valued at USD 86.7 Million in 2024 and is poised to grow from USD 93.72 Million in 2025 to USD 174.76 Million by 2033, growing at a CAGR of 8.1% during the forecast period (2026–2033). 

In May 2023, the International Vaccine Institute (IVI) began clinical development of DuoChol, a new low-cost oral cholera vaccine (OCV) in capsule form. With funding support from the Wellcome Trust and the Swedish government, IVI is preparing to conduct a Phase I clinical trial of the vaccine in Sweden. 'Valneva SE (France) ', 'Sanofi (France) ', 'Emergent BioSolutions (USA) ', 'EuBiologics (South Korea) ', 'Shantha Biotechnics (India) ', 'Hilleman Laboratories (Singapore) ', 'Astellas Pharma (Japan) ', 'Incepta Vaccine (Bangladesh) ', 'Vabiotech (France) ', 'Bharat Biotech (India) ', 'Biological E. (India) ', 'Serum Institute of India (India) ', 'Panum Institute (Denmark) ', 'Walter Reed Army Institute of Research (USA) ', 'National Institutes of Health (NIH) (USA) ', 'World Health Organization (WHO) (Switzerland) ', 'Centers for Disease Control and Prevention (CDC) (USA) ', 'Medecins Sans Frontières (MSF) (Switzerland) ', 'PATH (USA) '

The development of creative methods to new cholera vaccines, increased awareness of cholera preventative care, and adoption of unhealthy lifestyle habits including poor sanitation and consumption of tainted food are the factors anticipated to propel the growth of the cholera vaccines market. Additionally, a greater focus on immunisation campaigns by the government has fueled the market expansion for cholera vaccines. The global cholera vaccines market, however, may be hindered by the FDA's stricter criteria and longer approval process for new drugs.

The global market is primarily driven by the increasing prevalence of cholera among the general population. This is due to poor sanitation and hygiene conditions in rural and geographically remote areas. Furthermore, rising public awareness of the availability of cholera vaccines has boosted product demand.

The market is segmented into North America, Europe, Asia Pacific, Latin America and the Middle East and Africa (MEA). According to regional analysis, Asia-Pacific has the largest market share. This is due to increased access to effective preventive measures, rise in public awareness of the disease, and the disease's high incidence rate. Europe is also expected to grow steadily during the forecast period, owing to the region's well-established healthcare infrastructure. North America, on the other hand, is expected to grow at a faster rate during the forecast period, owing to rising consumption of contaminated food, a lack of appropriate hygiene, and an increasing number of migrants. At the same time, increased R&D activities, rising public awareness of vaccination, and rising government initiatives to conduct immunisation programmes would all contribute to the growth of the cholera vaccine market in this region.